290: CE: Using Novel Targeted Treatment for Canine Allergic and Atopic Dermatitis

The Vet Blast Podcast presented by dvm360

Sponsored by Elanco.
Unlike conventional treatments for canine allergic and atopic dermatitis, novel targeted therapies provide rapid relief with a reduced risk for adverse events. In this podcast, Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, react to the availability of a once-daily oral JAK inhibitor, highlighting it as a significant advancement in managing difficult skin conditions in dogs.
Learning Objectives:

• Understand the various causes of canine allergic and atopic dermatitis.
• Gain insight into using available treatment options to manage canine allergic and atopic dermatitis.
• Learn how Zenrelia™ (ilunocitinib tablets) can be used to offer dogs relief from pruritus associated with allergic and atopic dermatitis.

DISCLAIMER

Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1649
INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning.

For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.